Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobicistat-boosted Atazanavir or Darunavir and F/TAF in HIV-1 Infected Pediatric Participants
NCT02016924Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jan 2014
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of cobicistat, emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Started Jan 2014; status: active, not recruiting.
02
Drugs
cobicistatemtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02016924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02016924.